Datapoint: Incyte Scores Merkel Cell Carcinoma Nod for Zynyz

The FDA last week approved Incyte Corp.’s Zynyz for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC), a rare form of skin cancer. The PD-1 inhibitor will join oncology heavyweights in MCC market basket — Merck’s Keytruda and Bristol Myers Squibb’s Opdivo. Under the medial benefit, Opdivo is currently the most advantaged MCC therapy, holding covered or better status for 89% of all insured lives. Keytruda follows closely behind at 88%.

SOURCE: MMIT Analytics, as of 3/27/23

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 29

Datapoint: Optum Rx to Launch New Drug Pricing Model

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 28

Datapoint: Point32Health Offers In-Home Urgent Care

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 23

Datapoint: Centene Pledges Nearly $1B for Affordable Housing

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today